EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Heterogeneity in Cancer

William J MacDonald iD, Connor Purcell iD, Maximilian Pinho-Schwermann, Nolan M Stubbs, Praveen R Srinivasan iD, Wafik S El-Deiry iD

Cancers · 28.01.2025 · 17 (3) · 441

DOI: 10.3390/cancers17030441 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 28.01.2025. Verfasst von William J MacDonald und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Translational Oncology and Experimental Cancer Therapeutics, The Warren Alpert Medical School, Brown University, Providence, RI 02903, …. Die Arbeit wurde bisher 111-mal zitiert (Crossref) und nennt 165 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer heterogeneity is a major challenge in oncology, complicating diagnosis, prognostication, and treatment. The clinical heterogeneity of cancer, which leads to differential treatment outcomes between patients with histopathologically similar cancers, is attributable to molecular diversity manifesting through genetic, epigenetic, transcriptomic, microenvironmental, and host biology differences. Heterogeneity is observed between patients, individual metastases, and within individual lesions. This review discusses clinical implications of heterogeneity, emphasizing need for personalized approaches to overcome challenges posed by cancer’s diverse presentations. Understanding of emerging molecular diagnostic and analytical techniques can provide a view into the multidimensional complexity of cancer heterogeneity. With over 90% of cancer-related deaths associated with metastasis, we additionally explore the role heterogeneity plays in treatment resistance and recurrence of metastatic lesions. Molecular insights from next-generation sequencing, single-cell transcriptomics, liquid biopsy technology, and artificial intelligence will facilitate the development of combination therapy regimens that can potentially induce lasting and even curative treatment outcomes.

Schlagwörter

Stichwörter der Autor:innen

cancer heterogeneitydrug resistanceepigenetics

Autor:innen und Institutionen

  • Laboratory of Translational Oncology and Experimental Cancer Therapeutics, The Warren Alpert Medical School, Brown University, Providence, RI 02903, USA.
  • Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School, Brown University, Providence, RI 02903, USA.
  • Legorreta Cancer Center at Brown University, The Warren Alpert Medical School, Brown University, Providence, RI 02903, USA.
  • Morehouse School of Medicine, Atlanta, GA 30310, USA.
  • The Joint Program in Cancer Biology, Brown University and Brown University Health, Providence, RI 02903, USA.
  • Hematology-Oncology Division, Department of Medicine, Rhode Island Hospital, Brown University, Providence, RI 02903, USA.

ORCID-Profile: William J MacDonald, Connor Purcell, Praveen R Srinivasan, Wafik S El-Deiry

Zitieren

APA

MacDonald, W. J., Purcell, C., Pinho-Schwermann, M., Stubbs, N. M., Srinivasan, P. R., & El-Deiry, W. S. (2025). Heterogeneity in Cancer. Cancers, 17(3), 441. https://doi.org/10.3390/cancers17030441

Vancouver

MacDonald WJ, Purcell C, Pinho-Schwermann M, Stubbs NM, Srinivasan PR, El-Deiry WS. Heterogeneity in Cancer. Cancers. 2025;17(3):441. doi:10.3390/cancers17030441

BibTeX
@article{MacDonald2025,
  author = {MacDonald, William J and Purcell, Connor and Pinho-Schwermann, Maximilian and Stubbs, Nolan M and Srinivasan, Praveen R and El-Deiry, Wafik S},
  title = {Heterogeneity in Cancer},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {3},
  pages = {441},
  doi = {10.3390/cancers17030441}
}
Kostenlos starten →